


J M D C



Supplementary materials concerning acquisition of shares in Cancerscan Inc. (to make it JMDC's subsidiary)

JMDC Inc.

December 28, 2023



Overview of Cancerscan Inc.

On December 28, 2023, JMDC decided to acquire Cancerscan's shares and Cancerscan will join the JMDC Group.

Company overview

Company name: Cancerscan Inc.

Address: 1-3-8 Nishi-Gotanda, Shinagawa-ku, Tokyo

Representative: Jun Fukuyoshi

Establishment: November 19, 2008

Strengths

1

Build strong relationships with local governments

Since the launch of the program to improve the specific health checkup participation rate, Cancerscan has established strong relationships with more than 700 of the approximately 1,700 local governments in just nine years.

2

Abundant achievements in the field of preventive medicine

Based on a relationship of trust with local governments, Cancerscan accumulates health checkups data and claims data in local governments and returns it in a form that truly contributes to the public interest.


3

Highly specialized team

The management team includes three Harvard graduate school graduates, and has expertise in marketing, public health, data analysis, and investment.


Challenges of regional preventive medicine in Japan that Cancerscan aims to solve

The National Health Insurance enrollees (mainly the elderly aged 65 and over) that Cancerscan approaches face three major challenges, and Cancerscan recognizes that its mission is to solve these challenges.




1. Regular medical checkup participation rate of National Health Insurance enrollees

Half compared to the average health insurance union's medical checkup participation rate of about 80%, and 90% excluding dependents.



2. Medical care required rate of those who receive National Health Insurance medical checkups

Percentage of those who required medical care for one or more of blood pressure, blood glucose, and lipids (Cancerscan survey).




3. Untreated rate of those who required medical care under National Health Insurance

Percentage of those who are estimated to remain untreated after receiving a diagnosis requiring medical treatment based on specified medical checkups (Cancerscan survey)


Strengths of Cancerscan : (1) Strong relationships with local governments

Since the launch of the project to improve the specific health checkup participation rate, Cancerscan has established strong relationships with more than 700 of the approximately 1,700 local governments in just nine years. This is due to Cancerscan's strong track record in the field of preventive medicine.

Number of local government clients



Market share in local governments



Strengths of Cancerscan : (2) Abundant achievements in the field of preventive medicine

Through the provision of services to local governments, Cancerscan has accumulated unique data assets derived from the National Health Insurance and local governments. By returning these health data to society and people, Cancerscan is promoting initiatives that contribute to the extension of healthy life expectancy.

Data assets accumulated by **Cancerscan**

8.8 million people in total

(Health checkup data and claims data)




"Providing a Healthy and Rich Life for All Individuals"

Leveraging data and ICT solutions
to create a sustainable healthcare system


JMDC Policies

We will expand our data and business areas in an ecosystem where we provide data-driven services in various areas in the healthcare industry, receive data returns, and further evolve our services.



Sharing of assets and know-how of both companies : A unique combination to realize social issues


JMDC, with strong support from health insurance unions, and Cancerscan, with strong support from local governments, will join forces and share their know-how to provide a unique solution to the problems faced by Japan's payers and national health care costs.



Overwhelming position in Healthcare Big Data :

Establishing a dominant presence in the medical data market

Cancerscan's participation in the Group will enable us to establish a dominant presence in the local government field in terms of client base and data base, and to build a database that surpasses those of our competitors.



Note: Major players were selected by us based on the "Survey of Japanese databases in Japan available for clinical/pharmacoepidemiology by the Medical and healthcare database utilization committee of the Japanese Society for Pharmacoepidemiology" and the published materials of each company.

Our stance on the use of data : Data utilization based on trust with data holders

We believe that in the utilization of data, it is important to build a relationship of trust with data holders and to foster an understanding of the significance of the utilization of data. As in the past, we will continue to comply with various laws and regulations, and return the benefits to society and people through a relationship of trust with data holders.

1 s t

Solid and trusting relationship with payers

2 n d

Foster understanding of data utilization

3 r d

Compliance with various laws and regulations
and returning profits to society and people

This document is intended to provide corporate and other information concerning JMDC Inc. ("JMDC") and its group. It is not intended to solicit people for acquisition of shares and securities issued by JMDC, either in Japan or any other country.

Forward-looking statements in this document, including the JMDC Group's goals, plans, estimates, and forecasts, merely reflect decisions or ideas of the JMDC Group as of the time of writing. The actual results of the Group, including operating results and financial position, may vary greatly from the content of this document and assumptions based on the content depending on the economic situation at home and abroad, industrial trends, business competition, securing of human resources, technical innovation, and other factors of the business environment.

The information described in this document concerning the industry, market trends, economic situation, etc. was prepared based on the information available as of the time of writing and the JMDC Group provides no warranty as to the authenticity, accuracy, reasonableness, and completeness of such information. The information regarding other companies, etc., described in this document is quoted from public information or data prepared by third parties, and JMDC has not independently verified and does not guarantee the accuracy and appropriateness of such information. In addition, this document may describe information based on the JMDC Group's judgment, forecast, or estimation about the industry, market trends, economic situations, etc. Such information, however, merely reflects decisions or ideas as of the time of writing and the actual values may greatly differ from the information. The information regarding potential profit-earning opportunities for JMDC Group in this document is only an indication of the potential (scale) of future profit-earning opportunities that JMDC currently assumes based on certain assumptions, and does not represent our forecast, plan, estimate, or target for our performance at a specific point in the future. In addition, actual results may differ materially from those described in this document.

Financial data and other indicators of other companies cannot be directly compared with the corresponding indicators of JMDC due to differences in accounting standards, calculation methods, etc. Future changes in circumstances may affect the content of this document, however, JMDC takes no responsibility for updating or correcting this document. The content of this document is subject to change without prior notice.



J M D C